61 Results

People

  1. Kelsen
    Kelsen
  2. Casper
    Casper
  3. Aghajanian
    Aghajanian
  4. Schwartz
    Schwartz
  5. Bajorin
    Bajorin
  6. De Angelis
    De Angelis
  7. Lassman
    Lassman
  8. Motzer
    Motzer
  9. O'Reilly
    O'Reilly
  10. Abou-Alfa
    Abou-Alfa

Groups

  1. Department of Medicine (45)
  2. Solid Tumor Oncology Division (34)
  3. Hematologic Malignancies, Division of (13)
  4. Center for Pancreatic Cancer Research (11)
  5. Gastrointestinal Oncology Service (9)
  6. Biostatistics Service (8)
  7. Center for Hematologic Malignancies (8)
  8. Epidemiology and Biostatistics (8)
  9. Genitourinary Oncology Service (8)
  10. Surgery (8)
  1. "phase ii"
Formats
  1. Journal Article (49)
  2. Meeting Abstract (12)
Groups
  1. Department of Medicine (45)
  2. Solid Tumor Oncology Division (34)
  3. Hematologic Malignancies, Division of (13)
  4. Center for Pancreatic Cancer Research (11)
  5. Gastrointestinal Oncology Service (9)
  6. Biostatistics Service (8)

More Groups

People
  1. David Kelsen (7)
  2. Ephraim Casper (6)
  3. Carol Aghajanian (5)
  4. Gary Schwartz (5)
  5. Dean Bajorin (4)
  6. Andrew Lassman (3)

More People

Years
  1. 2024 (2)
  2. 2023 (8)
  3. 2022 (4)
  4. 2019 (2)
  5. 2018 (1)
  6. 2017 (1)

More Years

Publications
  1. Investigational New Drugs (14)
  2. Clinical Lymphoma, Myeloma and Leukemia (11)
  3. Gynecologic Oncology (6)
  4. International Journal of Radiation Oncology, Biology, Physics (5)
  5. Cancer (3)
  6. European Journal of Cancer (3)

More Publications

Publishers
  1. Elsevier Inc. (28)
  2. Springer (16)
  3. Oxford University Press (3)
  4. Wiley Blackwell (3)
  5. Elsevier Science, Inc. (2)
  6. Lippincott Williams & Wilkins (2)

More Publishers

Results (61)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study evaluating the effect of intensity modulated postmastectomy radiation therapy on implant failure rates in breast cancer patients with immediate, 2-stage implant reconstruction with an MRI imaging correlative substudy
    Journal Article

    Khan, A. J.; Marine, C. B.; Flynn, J.; Tyagi, N.; Zhang, Z.; Thor, M.; Gelblum, D.; Mehrara, B.; McCormick, B.; Powell, S. N.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients
    Journal Article

    Lee, V.; Parkinson, R.; Zahurak, M.; Cope, L.; Cercek, A.; Verheul, H.; Gootjes, E.; Lenz, H. J.; Iqbal, S.; Jones, P.; more...
    International Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: Results of a phase II study (MOONSTONE/GOG-3032)
    Journal Article

    Randall, L. M.; O'Malley, D. M.; Monk, B. J.; Coleman, R. L.; Gaillard, S.; Adams, S.; Duska, L. R.; Dalton, H.; Holloway, R. W.; Huang, M.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma (RRMM): Extended follow-up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martínez-Lopez, J.; Koehne, G.; Jethava, Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the MajesTEC-1 study
    Meeting Abstract

    Usmani, S. Z.; Karlin, L.; Benboubker, L.; Nahi, H.; San-Miguel, J.; Trancucci, D.; Qi, K.; Stephenson, T.; Puchalt, A. P.; Chastain, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Dreyling, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase II study results of lisocabtagene maraleucel (liso-cel) in patients with R/R follicular lymphoma (FL)
    Meeting Abstract

    Nastoupil, L. J.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Ortega, J. L. R.; Kuruvilla, J.; Jager, U.; Cartron, G.; Izutsu, K. I.; Dreyling, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • ASC2ESCALATE: A US, phase II open-label, single-arm, dose-escalation study of asciminib monotherapy in second-line (2L) and first-line (1L) treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP)
    Meeting Abstract

    Atallah, E.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P.; Yang, D.; Laine, D.; Sabo, J.; Gu, E. N.; Cortes, J.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save